CD8 和程序性死亡配体 1 表达对可切除非小细胞肺癌患者的预后影响。
Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.
机构信息
Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, 51353, Republic of Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, 51472, Republic of Korea.
出版信息
Br J Cancer. 2019 Mar;120(5):547-554. doi: 10.1038/s41416-019-0398-5. Epub 2019 Feb 12.
BACKGROUND
The prognostic impact of the expression of CD8 and programmed death-ligand 1 (PD-L1) has not been established in patients with resectable non-small cell lung cancer (NSCLC).
METHODS
Surgical tissue specimens were obtained from 136 patients with NSCLC who underwent surgical resection. The expression levels of CD8 and PD-L1 were assessed using tissue microarrays and immunohistochemistry.
RESULTS
The CD8-positive group showed significant increases in overall survival (OS) (median, not reached [NR] vs. 28.452 months) and relapse-free survival (RFS) (median, NR vs. 14.916 months) compared with the CD8-negative group. In contrast to CD8, the PD-L1-negative group demonstrated significant increases in OS (median, NR vs. 29.405 months) and RFS (median, 63.573 vs. 17.577 months) compared with the PD-L1-positive group. Two prognostic groups were stratified according to CD8/PD-L1 expression: group 1 (CD8-positive/PD-L1-negative) vs. group 2 (CD8/PD-L1: positive/positive, negative/negative, negative/positive). Group 1 had better OS (median, NR vs. 29.405 months) and RFS (median, NR vs. 17.577 months) than group 2. Multivariate analysis indicated that group 1 constituted an independent favourable prognostic factor for OS (hazard ratio [HR], 0.329, p = 0.001) and RFS (HR, 0.293; p < 0.001).
CONCLUSIONS
Positive CD8 and negative PD-L1 expression together may be favourable prognostic markers in resectable NSCLC.
背景
CD8 和程序性死亡配体 1（PD-L1）的表达对可切除的非小细胞肺癌（NSCLC）患者的预后影响尚未确定。
方法
对 136 例接受手术切除的 NSCLC 患者的手术组织标本进行了研究。使用组织微阵列和免疫组织化学评估 CD8 和 PD-L1 的表达水平。
结果
与 CD8 阴性组相比，CD8 阳性组的总生存期（OS）（中位数，未达到[NR] vs. 28.452 个月）和无复发生存期（RFS）（中位数，NR vs. 14.916 个月）均显著增加。与 CD8 相反，PD-L1 阴性组的 OS（中位数，NR vs. 29.405 个月）和 RFS（中位数，63.573 vs. 17.577 个月）均显著高于 PD-L1 阳性组。根据 CD8/PD-L1 表达情况将患者分为两组：组 1（CD8 阳性/PD-L1 阴性）和组 2（CD8/PD-L1：阳性/阳性、阴性/阴性、阴性/阳性）。组 1 的 OS（中位数，NR vs. 29.405 个月）和 RFS（中位数，NR vs. 17.577 个月）均优于组 2。多变量分析表明，组 1 是 OS（风险比[HR]，0.329，p=0.001）和 RFS（HR，0.293；p<0.001）的独立预后因素。
结论
CD8 阳性和 PD-L1 阴性的表达可能是可切除 NSCLC 的有利预后标志物。
Zotero 插件